[Featured Stock] ABL Bio, the Most Attractive New Drug Development... Abundant Cash Is a Bonus

[Asia Economy Reporter Hyungsoo Park] ABL Bio is showing strong performance. Positive reviews from the Yeouido securities community seem to be having a favorable impact on its stock price.

As of 11:04 AM on the 16th, ABL Bio is trading at 24,500 KRW, up 4.48% from the previous day.

Jaekyung Park, a researcher at Hana Securities, stated, "ABL Bio is a new drug development company possessing bispecific antibody technology," and introduced, "The bispecific antibody areas that ABL Bio focuses on are the 4-1BB bispecific antibody (Grabody T, I) and the IGF-1R-based bispecific antibody Grabody B, which enhances blood-brain barrier permeability."

He continued, "Grabody B utilizes IGF-1R to increase BBB permeability and the amount of antibody delivered to the brain," adding, "An FDA IND amendment application is underway for the pipeline ABL301, which applies Grabody B."

He emphasized, "With the approval of Alzheimer's antibody treatments approaching, attention is turning to the expandability of Grabody B," and highlighted, "Since many unmet needs in amyloid beta antibody treatments involve reducing dosage, the approval of lecanemab could be a good opportunity to expand the application scope of Grabody B."

Byungguk Park, a researcher at NH Investment & Securities, analyzed, "Next year, it will be a leading company in the CNS trend," and added, "The value of Grabody B is growing steadily."

He pointed out, "On the 14th, Roche disclosed the failure of the phase 3 trial for the Alzheimer's therapeutic gantenerumab," and emphasized, "The limited reduction of plaques is presumed to be the main cause, which will increase interest in RG6102, currently in phase 1b/2a with its own BBB technology."

Additionally, he explained, "Biogen's lecanemab will also reveal detailed data at CTAD," and noted, "Biogen mentioned a positive perspective on applying the BBB platform to lecanemab."

Researcher Park predicted, "The value of the BBB platform will continue to rise," and forecasted, "The phase 1 amendment for the Parkinson's treatment ABL301 (applying Grabody B), licensed out to Sanofi, will begin clinical trials for repeated dosing groups this year."

He added, "The operating profit on a consolidated basis for the third quarter was 25 billion KRW, reflecting the recognition of a $20 million milestone payment from Sanofi," and explained, "In the fourth quarter, a milestone payment of $25 million is expected to be recognized." Furthermore, he stated, "The company has secured 150 billion KRW in cash," and commented, "Given the challenging environment for cash acquisition, its relative attractiveness is increasing."